04:32 PM EDT, 10/09/2025 (MT Newswires) -- Nurix Therapeutics ( NRIX ) reported a fiscal Q3 net loss Thursday of $1.03 per diluted share, wider than a loss of $0.67 a year ago.

Analysts polled by FactSet expected a GAAP loss of $0.84 per share and a loss of $0.82 a share.

Revenue for the quarter ended Aug. 31 was $7.9 million, down from $12.6 million a year earlier.

Analysts surveyed by FactSet expected $16 million.

The shares were down over 5% in after-hours activity.